¼¿ï´ëÇб³¾î¸°À̺´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Hereditary Gynecologic Cancer Symposium : 2018-11-17 ±³À°ÀÏÀÚ : 2018-11-17 ±³À°Àå¼Ò : ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó 1, 2 °ÀÇ½Ç ±³À°ÁÖÁ¦ : Hereditary Gynecologic Cancer Symposium ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ ´ã´çÀÚ : ½Å½ÃÀº ¿¬¶ôó : 02-512-0044 À̸ÞÀÏ : office@sgo.or.kr ±³À°Á¾·ù : ¿Ü°ú, »êºÎÀΰú Âü¼®¿¹»óÀοø : 100¸í Èñ¸ÁÆòÁ¡ : 5Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ ¼¼ºÎ¼ö°·á : 0¿ø ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 09:30~09:50 Basic of hereditary gynecologic cancer ±Çº´¼ö(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 09:50~10:10 Pathological re-consideration of hereditary predisposition À¯Á¾¿ì(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 10:10~10:30 Cancer penetration & interaction of BRCA and MMR mutation ±è¹Î±Ô(¼º±Õ°üÀÇ´ë) Åä·Ð 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 10:30~10:35 Åä·Ð À¯ÇåÁ¾(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 10:40~11:00 Japanese perspectives on HGC Akira Hirasawa(Keio University) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 11:00~11:20 HGC management: the current situation of JFCR Kohei Omatsu(Cancer Institute Hospital) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 11:20~11:40 Taiwanease perspective on HGC Angela Chao(Chang-Gung University) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 11:40~12:00 HGC management: perspectives of Thai Gynecologic Cancer Society Arb-aroon Lertkhachonsuk(Mahidol University) Åä·Ð 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 12:00~12:10 Åä·Ð () ½Ä»ç 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 12:10~13:20 ½Ä»ç () ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 13:20~13:40 Highlights of the Korean Hereditary Breast Cancer Study ±è¼º¿ø(´ë¸²¼º¸ðº´¿ø) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 13:40~14:00 Establishing hereditary statistics in the big data platform ¹Úº¸¿µ(ÇѾçÀÇ´ë) Åä·Ð 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 14:00~14:05 Åä·Ð Á¤´ëÈÆ(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 14:10~14:30 Clinical treatment outcome as per the g/sBRCA, other HR and MMR mutation À̼ºÁ¾(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 14:30~14:50 Immunotherapy using hereditary predisposition ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 14:50~15:10 Surgical & medical cancer prevention for mutation carriers ÃÖ¹Îö(Â÷ÀÇ´ë) Åä·Ð 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 15:10~15:15 Åä·Ð ±è¹Ì°æ(ÀÌÈÀÇ´ë) ÈÞ½Ä 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 15:20~15:40 Coffe Break () ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 15:40~16:00 TBD ¹ÚÂùÀÌ(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 16:00~16:20 Position statement on genetic test and managmenet of HGC ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 11-17 ÀÓ»ó 1, 2 °ÀÇ½Ç 16:20~16:40 Ethical, legal issue of genetic testing & counseling ±è¹Ì¼±(Â÷ÀÇ´ë)
|